MedTrace Logo

Effects of Pulmonary Diseases and Their Treatment on Cardiac Function

NCT05042219 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-07-16

No results posted yet for this study

Summary

While the bidirectional relationship between the lung and the right heart are well studied, the cardiopulmonary interactions between the lung and the left heart are largely unresearched and not well understood. However, in recent years, there is a growing evidence that partially explains the bidirectional interaction between COPD and left heart. Systemic inflammation with multiorgan involvement is thought to play a role in COPD as a systemic disease. Some therapeutic approaches to COPD also appear to influence these cardiopulmonary interactions. While understanding these interactions is very important for clinicians, scientific data are scarce. Cardiac magnetic resonance imaging (cardiac MRI) is the gold standard for assessing cardiac function and dimensions as well as myocardial inflammation. Despite this excellent suitability of cardiac MRI for the assessment of cardiovascular function, only few studies have investigated cardiac function and myocardial structure in patients with pulmonary disease using cardiac MRI. Such a study is therefore very important for understanding the effects of pulmonary disease and its management on the heart.

The objective is to determine cardiac function in patients with pulmonary disease and to analyze the cardiovascular effects of the treatment of the pulmonary disease.

Specifically, the following will be studied:

* Using cardiac MRI: Cardiac function and volumes and indications of myocardial fibrosis and edema in patients with chronic pulmonary disease at the time of first diagnosis.
* the vascular function of pulmonary arteries in these patients, also using cardiac MRI
* the relationship between pulmonary function parameters and cardiac dysfunction to identify patients at increased risk, if applicable.
* Echocardiographic assessment of left heart including strain analysis.
* the course of these cardiovascular parameters (using cardiac MRI and echocardiography) 3-6 months after initiation of guideline-based therapy for pulmonary disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter

Sponsors & Collaborators

  • Ayham Daher

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2026-09-14
Completion
2026-12-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05042219 on ClinicalTrials.gov